On November 3, 2017 OPKO Health, Inc. (NASDAQ: OPK) reported that it will announce its operating and financial results for the three and nine months ended September 30, 2017, after the close of the U.S. financial markets on Wednesday, November 8, 2017 (Press release, Opko Health, NOV 3, 2017, View Source [SID1234521803]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OPKO’s senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Wednesday, November 8, 2017.
Conference Call & Webcast Information

WHEN: Wednesday, November 8, 2017 at 4:30 p.m. Eastern time.
DOMESTIC DIAL-IN: (866) 634-2258
INTERNATIONAL DIAL-IN: (330) 863-3454
PASSCODE: 8399217
WEBCAST: View Source

For those unable to participate in the live conference call or webcast, a replay will be available beginning November 8, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 8399217. The replay can be accessed for a period of time on OPKO’s website at View Source.

On November 3, 2017, results of AVEO’s ongoing phase 1 portion of the TiNivo study, a phase 1/2 multicenter trial of tivozanib (FOTIVDA) in combination with Bristol-Myers Squibb’s nivolumab (OPDIVO), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced renal cell carcinoma (RCC) are being presented at the 16th International Kidney Cancer Symposium in Miami, Florida, in an oral presentation titled “TiNivo: A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma” by Laurence Albiges, M.D., Ph.D., Head, Genitourinary Unit, Institute Gustave Roussy, and a lead investigator of the study (Filing, 8-K, AVEO, NOV 3, 2017, View Source [SID1234521555]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The phase 1 portion of the trial enrolled six patients, three with previously untreated metastatic RCC and three who had received first-line treatment. RCC tumor histology included five clear cell (one with sarcomatoid features) and one papillary. Tivozanib was administered to patients in two escalating dose cohorts (1.0 mg/QD and 1.5 mg/QD) in combination with nivolumab at a constant 240 mg every 2 weeks. The combination was well tolerated to the full dose and schedule of single agent tivozanib, with no dose limiting toxicities. The most common adverse events (any grade) were hypertension, asthenia and decreased appetite. No grade 4 adverse events were reported. Two grade 3 events were reported beyond cycle 1 (stomatitis and increased ALT), which did not lead to study discontinuation and were managed concurrently. Unconfirmed best response to date includes a 67% (4/6) partial response (PR) rate and a 100% disease control rate (PR + stable disease). Enrollment of approximately 20 patients in the phase 2 portion of the trial is ongoing.

AVEO is encouraged by the promising preliminary tolerability and activity results from the TiNivo trial, and believes that they begin to underscore the unique potential of tivozanib-immunotherapy combinations. The Company expects to present the results of the phase 2 portion of the TiNivo trial in the first half of 2018, and anticipates initiating additional combination studies in the next year.

The information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

On November 3, 2017 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported that new data will be presented in an oral presentation and a trial in progress poster at the upcoming CTOS meeting that will be held November 8-11 at the Grand Wailea Resort in Hawaii (Press release, Adaptimmune, NOV 3, 2017, View Source [SID1234521554]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sandra P. D’Angelo of Memorial Sloan Kettering Cancer Center will be presenting an update on the company’s ongoing study of NY-ESO SPEAR T-cells in synovial Sarcoma. There will also be a trial in progress poster for the ongoing study of NY-ESO SPEAR T-cells in Myxoid/Round Cell Liposarcoma (MRCLS). Details are below:

Oral Presentation:

Title: Open Label Non-Randomized Multi-Cohort Pilot Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells in HLA-A2+ Patients with Synovial Sarcoma (NCT01343043)
– Abstract ID: 2804696
– Session Title: Symposium 1: Medical, Pediatric and Young Adult Oncology
– Session Time: November 9, 2017 from 10:30 AM to 12:00 PM
– Location: Haleakala 1
Trial in Progress Poster:

Title: A Pilot Study of NY-ESO-1 SPEAR T-Cells in Subjects with Advanced Myxoid/Round Cell Liposarcoma (NCT02992743)
– Abstract ID: 2804696
– Presentation time: The poster will be on display throughout the meeting.
– Poster Session: November 9, 2017 from 5:30 PM to 6:30 PM
– Location: Haleakala 2 & 3

On November 3, 2017 Portola Pharmaceuticals (Nasdaq:PTLA) reported that Bill Lis, chief executive officer, will present at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, at 8:40 a.m. Mountain Time in Scottsdale, AZ (Press release, Portola Pharmaceuticals, NOV 3, 2017, View Source [SID1234521546]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and available for replay for 30 days following the presentation on the Credit Suisse website.

On November 3, 2017 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, 2017, at The Phoenician in Scottsdale, Arizona (Press release, Karyopharm, NOV 3, 2017, View Source [SID1234521544]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!